Literature DB >> 26752675

Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.

Kalli C Catcott1, Molly A McShea1, Carl Uli Bialucha2, Kathy L Miller3, Stuart W Hicks1, Parmita Saxena2, Thomas G Gesner2, Mikias Woldegiorgis3, Megan E Lewis1, Chen Bai1, Michael S Fleming1, Seth A Ettenberg2, Hans K Erickson1, Nicholas C Yoder1.   

Abstract

Antibody-drug conjugates (ADCs) are of great interest as targeted cancer therapeutics. Preparation of ADCs for early stage screening is constrained by purification and biochemical analysis techniques that necessitate burdensome quantities of antibody. Here we describe a method, developed for the maytansinoid class of ADCs, enabling parallel conjugation of antibodies in 96-well format. The method utilizes ∼ 100 µg of antibody per well and requires <5 µg of ADC for characterization. We demonstrate the capabilities of this system using model antibodies. We also provide multiple examples applying this method to early-stage screening of maytansinoid ADCs. The method can greatly increase the throughput with which candidate ADCs can be screened in cell-based assays, and may be more generally applicable to high-throughput preparation and screening of different types of protein conjugates.

Entities:  

Keywords:  Antibody; antibody-drug conjugate; conjugation; high-throughput; maytansinoid; protein chemistry

Mesh:

Substances:

Year:  2016        PMID: 26752675      PMCID: PMC4966849          DOI: 10.1080/19420862.2015.1134408

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  39 in total

1.  Adopting a practical statistical approach for evaluating assay agreement in drug discovery.

Authors:  Dongyu Sun; Adrian Whitty; James Papadatos; Miki Newman; Jason Donnelly; Scott Bowes; Serene Josiah
Journal:  J Biomol Screen       Date:  2005-08

2.  Formulation development of antibodies using robotic system and high-throughput laboratory (HTL).

Authors:  Hui Zhao; Olivier Graf; Nebojsa Milovic; Xiaosong Luan; Markus Bluemel; Markus Smolny; Kurt Forrer
Journal:  J Pharm Sci       Date:  2010-05       Impact factor: 3.534

Review 3.  Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs.

Authors:  Christian Jost; Andreas Plückthun
Journal:  Curr Opin Struct Biol       Date:  2014-07-15       Impact factor: 6.809

4.  High-throughput generation and engineering of recombinant human antibodies.

Authors:  B Krebs; R Rauchenberger; S Reiffert; C Rothe; M Tesar; E Thomassen; M Cao; T Dreier; D Fischer; A Höss; L Inge; A Knappik; M Marget; P Pack; X Q Meng; R Schier; P Söhlemann; J Winter; J Wölle; T Kretzschmar
Journal:  J Immunol Methods       Date:  2001-08-01       Impact factor: 2.303

5.  Discovery of internalizing antibodies to tumor antigens from phage libraries.

Authors:  Yu Zhou; James D Marks
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

6.  Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions.

Authors:  Xiuru Li; Tao Fang; Geert-Jan Boons
Journal:  Angew Chem Int Ed Engl       Date:  2014-05-23       Impact factor: 15.336

7.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

Review 8.  Antibody-drug conjugates: an emerging concept in cancer therapy.

Authors:  Ravi V J Chari; Michael L Miller; Wayne C Widdison
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-20       Impact factor: 15.336

9.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Authors:  José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

10.  Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.

Authors:  Kathleen R Whiteman; Holly A Johnson; Michele F Mayo; Charlene A Audette; Christina N Carrigan; Alyssa LaBelle; Lawrence Zukerberg; John M Lambert; Robert J Lutz
Journal:  MAbs       Date:  2014-01-08       Impact factor: 5.857

View more
  2 in total

1.  High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries.

Authors:  Shin-Chen Hou; Hong-Sen Chen; Hung-Wei Lin; Wei-Ting Chao; Yao-Sheng Chen; Chi-Yu Fu; Chung-Ming Yu; Kai-Fa Huang; Andrew H-J Wang; An-Suei Yang
Journal:  Sci Rep       Date:  2016-08-23       Impact factor: 4.379

2.  Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.

Authors:  Alex R Nanna; Xiuling Li; Even Walseng; Lee Pedzisa; Rebecca S Goydel; David Hymel; Terrence R Burke; William R Roush; Christoph Rader
Journal:  Nat Commun       Date:  2017-10-24       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.